EP
KPTI icon

Eversept Partners’s Karyopharm Therapeutics KPTI Stock Holding History

Eversept Partners’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-23,800
Closed -$133K – 137
2026
Q1 		$133K Buy
+23,800
New +$181K 0.01% 120

Other funds holding KPTI

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Eversept Partners's KPTI Position: Q2 2026 in Review

Eversept Partners held its Karyopharm Therapeutics (KPTI) position steady in Q2 2026 at 276,174 shares worth $2.7M. The position accounts for 0.14% of the portfolio, ranked #85.

Eversept Partners first reported a position in KPTI in Q1 2024 and has held it in 8 quarters since. The position peaked at $7.57M in Q1 2024. 96 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

  • Eversept Partners held 276,174 shares of Karyopharm Therapeutics worth $2.7M as of Q2 2026.
  • Eversept Partners left its Karyopharm Therapeutics share count unchanged in Q2 2026.
  • Karyopharm Therapeutics made up 0.14% of Eversept Partners's portfolio in Q2 2026, its #85 holding.
  • Eversept Partners first reported a position in Karyopharm Therapeutics in Q1 2024 and has held it in 8 quarters since.
  • Eversept Partners's Karyopharm Therapeutics position peaked at $7.57M in Q1 2024.
  • 96 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.